| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 839 | 2021 |
| Swarm learning for decentralized and confidential clinical machine learning S Warnat-Herresthal, H Schultze, KL Shastry, S Manamohan, ... Nature 594 (7862), 265-270, 2021 | 746 | 2021 |
| Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19 JP Bernardes, N Mishra, F Tran, T Bahmer, L Best, JI Blase, D Bordoni, ... Immunity 53 (6), 1296-1314. e9, 2020 | 338 | 2020 |
| Drug‐resistant tuberculosis: an update on disease burden, diagnosis and treatment C Lange, D Chesov, J Heyckendorf, CC Leung, Z Udwadia, K Dheda Respirology 23 (7), 656-673, 2018 | 260 | 2018 |
| Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis NN Chegou, J Heyckendorf, G Walzl, C Lange, M Ruhwald European Respiratory Journal 43 (5), 1472-1486, 2014 | 210 | 2014 |
| What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi-and extensively drug-resistant tuberculosis J Heyckendorf, S Andres, CU Köser, ID Olaru, T Schön, E Sturegård, ... Antimicrobial agents and chemotherapy 62 (2), 10.1128/aac. 01550-17, 2018 | 132 | 2018 |
| S2k-Leitlinie: Tuberkulose im Erwachsenenalter T Schaberg, T Bauer, F Brinkmann, R Diel, C Feiterna-Sperling, W Haas, ... Pneumologie 71 (06), 325-397, 2017 | 112 | 2017 |
| Novel drugs against tuberculosis: a clinician's perspective ID Olaru, F von Groote-Bidlingmaier, J Heyckendorf, WW Yew, C Lange, ... European Respiratory Journal 45 (4), 1119-1131, 2015 | 105 | 2015 |
| Management of patients with multidrug-resistant tuberculosis C Lange, RE Aarnoutse, JWC Alffenaar, G Bothamley, F Brinkmann, ... The international journal of tuberculosis and lung disease 23 (6), 645-662, 2019 | 93 | 2019 |
| Detailed stratified GWAS analysis for severe COVID-19 in four European populations F Degenhardt, D Ellinghaus, S Juzenas, J Lerga-Jaso, M Wendorff, ... Human molecular genetics 31 (23), 3945-3966, 2022 | 91* | 2022 |
| Emergence of bedaquiline resistance in a high tuberculosis burden country E Chesov, D Chesov, FP Maurer, S Andres, C Utpatel, I Barilar, A Donica, ... European Respiratory Journal 59 (3), 2022 | 78 | 2022 |
| Bedaquiline-resistant tuberculosis: dark clouds on the horizon S Andres, M Merker, J Heyckendorf, B Kalsdorf, R Rumetshofer, A Indra, ... American journal of respiratory and critical care medicine 201 (12), 1564-1568, 2020 | 77 | 2020 |
| Diagnosis and management of systemic endemic mycoses causing pulmonary disease HJF Salzer, G Burchard, OA Cornely, C Lange, T Rolling, S Schmiedel, ... Respiration 96 (3), 283-301, 2018 | 75 | 2018 |
| Rapid genomic first-and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB S Feuerriegel, TA Kohl, C Utpatel, S Andres, FP Maurer, J Heyckendorf, ... European Respiratory Journal 57 (1), 2021 | 74 | 2021 |
| Time to culture positivity and sputum smear microscopy during tuberculosis therapy ID Olaru, J Heyckendorf, S Grossmann, C Lange PloS one 9 (8), e106075, 2014 | 64 | 2014 |
| Perspective for precision medicine for tuberculosis C Lange, R Aarnoutse, D Chesov, R Van Crevel, SH Gillespie, ... Frontiers in immunology 11, 566608, 2020 | 57 | 2020 |
| T-cell therapy: options for infectious diseases SK Parida, T Poiret, L Zhenjiang, Q Meng, J Heyckendorf, C Lange, ... Clinical Infectious Diseases 61 (suppl_3), S217-S224, 2015 | 56 | 2015 |
| Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis J Heyckendorf, ID Olaru, M Ruhwald, C Lange American journal of respiratory and critical care medicine 190 (4), 374-383, 2014 | 56 | 2014 |
| Tuberculosis treatment monitoring and outcome measures: new interest and new strategies J Heyckendorf, SB Georghiou, N Frahm, N Heinrich, I Kontsevaya, ... Clinical microbiology reviews 35 (3), e00227-21, 2022 | 55 | 2022 |
| Characterization of patients with chronic pulmonary aspergillosis according to the new ESCMID/ERS/ECMM and IDSA guidelines HJF Salzer, J Heyckendorf, B Kalsdorf, T Rolling, C Lange Mycoses 60 (2), 136-142, 2017 | 55 | 2017 |